Combination approach shows promise for treating rare, aggressive cancers
A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, ...
News Medical on MSN15h
New treatment combination improves outcomes for small cell bladder and prostate cancer patients
A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
Trial of Cretostimogene Monotherapy in BCG-Unresponsive NMIBC Accepted at the Society of Urologic Oncology (SUO) 25th Annual Meeting - IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- CG Oncology, ...
Armed robbery in Revesby21h
Combo Therapy Promising for Rare Aggressive Cancers
A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy ...
pharmaphorum5d
ESMO: NIAGARA backs Imfinzi in bladder cancer, but will FDA?
AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC ... was no way to tell if post-surgery use of the drug may be adding to toxicity without conferring a clinical ...
pharmaphorum2d
ESMO: Immunotherapy combos extend lives in bladder cancer
“It is very exciting that we have now identified a combination of treatments that ... of chemotherapy and immunotherapy in patients with metastatic bladder cancer,” said Dr Apolo, who noted ...
The Canadian Press on MSN13h
Former B.C. premier John Horgan dies at age 65, after third bout with cancer
Ambassador to Germany and former British Columbia premier John Horgan has died at the age of 65, after his third bout with ...
Medindia2d
Theragent and CellVax Therapeutics Announce First Patient Dosed in Phase 2 Trial of FK-PC101, a Novel Personalized Cancer Immunotherapy
Theragent Inc., a comprehensive CDMO focused on advancing next-generation cell-based therapies, has announced a significant milestone for both Theragent and its sponsor client, CellVax ...
Natera Announces Completion of Signatera™ Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the completion of a study ...
The Canadian Press on MSN13h
Former B.C. premier John Horgan, who connected with people, dies at 65
Horgan had been successfully treated for bladder cancer in 2008. "I am on leave from my position at the embassy and in ...
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform
Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that U.S.